预约演示

更新于：2025-05-07

Alcohol Withdrawal Delirium

戒酒性谵妄

更新于：2025-05-07

基本信息

别名

ALCOHOL WITHDRAWAL DELIRIUM TREMENS、ALCOHOLIC DELIRIUM、Alcohol Withdrawal Associated Autonomic Hyperactivity

+ [61]

简介

An acute organic mental disorder induced by cessation or reduction in chronic alcohol consumption. Clinical characteristics include CONFUSION; DELUSIONS; vivid HALLUCINATIONS; TREMOR; agitation; insomnia; and signs of autonomic hyperactivity (e.g., elevated blood pressure and heart rate, dilated pupils, and diaphoresis). This condition may occasionally be fatal. It was formerly called delirium tremens. (From Adams et al., Principles of Neurology, 6th ed, p1175)

关联

项与戒酒性谵妄相关的药物

Paraldehyde

副醛

靶点-

作用机制-

在研机构

Phebra Pty Ltd.

原研机构-

在研适应症

躁动 [+6]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期2009-08-31

Dexmedetomidine Hydrochloride

盐酸右美托咪定

靶点

ADRA2

作用机制

ADRA2激动剂

在研机构

BioXcel Therapeutics, Inc. [+15]

原研机构

Orion Oyj

在研适应症

躁郁症1型 [+13]

非在研适应症

急性缺血性卒中 [+13]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1999-12-17

项与戒酒性谵妄相关的临床试验

DRKS00036025

/ SuspendedN/AIIT

Delirium Prediction in the Emergency Department - DELPREDI

开始日期2025-04-01

申办/合作机构-

DRKS00033299

/ RecruitingN/AIIT

Delirium on Intensive Care Units. How does an educational intervention affect Delirium? - DEIN

开始日期2025-03-11

申办/合作机构-

DRKS00035499

/ SuspendedN/A

Evaluation of a specialist geriatric assessment in oral and maxillofacial surgery to identify patients at risk of postoperative delirium - a prospective clinical study

开始日期2025-01-01

申办/合作机构-

100 项与戒酒性谵妄相关的临床结果

登录后查看更多信息

100 项与戒酒性谵妄相关的转化医学

登录后查看更多信息

0 项与戒酒性谵妄相关的专利（医药）

登录后查看更多信息

2,211

项与戒酒性谵妄相关的文献（医药）

2025-04-01·Critical Care Nurse

Using the Modified Minnesota Detoxification Scale to Evaluate Alcohol Withdrawal Syndrome: An Integrative Review

Review

作者: Trojand, Torri ; Shamoun, Charles J. ; Morgan, Jaclynn

BackgroundAlcohol use disorder in the United States is increasing. Alcohol is the second most commonly abused drug worldwide, resulting in acute hospitalizations related to alcohol use and alcohol withdrawal syndrome. Management of alcohol withdrawal syndrome relies on screening tools to determine the need for treatment. The most commonly used tool is the Clinical Institute Withdrawal Assessment for Alcohol Scale–Revised (CIWA-Ar), which has not been validated for use in critical care units.ObjectiveTo evaluate whether the modified Minnesota Detoxification Scale (mMINDS) is more effective than the CIWA-Ar for evaluating acute withdrawal symptoms in patients in intensive care units.MethodsThis integrative review used the framework of Whittemore and Knafl. The literature was searched for studies related to mMINDS, neurocritical care, and critical care.ResultsNine articles were included in the review. The review revealed 3 outcomes: nurses preferred the mMINDS over the CIWA-Ar, assessments with the mMINDS tool was more accurate for patients with CIWA-Ar scores greater than 10, and patient outcomes were improved with use of the mMINDS. The mMINDS is preferred over the CIWA-Ar for managing alcohol withdrawal syndrome in patients in intensive care units because it is associated with shorter stays, less benzodiazepine use, and a decrease in delirium tremens.ConclusionThe findings regarding mMINDS can apply to both critical care and non–critical care settings. The mMINDS is preferred by nurses and results in more positive patient outcomes. The mMINDS is effective and should be used in critical care areas.

2025-04-01·Journal of Sleep Research

Agrypnia excitata: a human model to explore the derailment of sleep–wake cycle integrated control

Review

作者: Baldelli, Luca ; Provini, Federica ; Parrino, Liborio ; Cortelli, Pietro ; Mutti, Carlotta

SummaryThe commemoration of the 70th anniversary of rapid eye movement sleep discovery offers a unique possibility to reassess the peculiar organic condition of agrypnia excitata. Agrypnia excitata is characterized by a severe loss of sleep leading to a complete derangement of physiological sleep–wake cycle and body homeostasis. Agrypnia excitata is a definite clinico‐neurophysiological condition characterized by: (1) slow‐wave sleep loss with disruption of sleepwake cycle; (2) a 24‐hr motor and autonomic overactivity; and (3) peculiar episodes of oneiric stupor. Agrypnia excitata may happen within different pathophysiologies, such as delirium tremens, Morvan's syndrome and fatal familial insomnia, suggesting some general reflections on the composition and function of the cerebral neuronal network generating wake and sleep behaviour and regulating body homeostasis, with a focus on rapid eye movement sleep.

2025-04-01·Basic & Clinical Pharmacology & Toxicology

Prevalence of Patients Admitted to Intensive Care After Administration of Chlordiazepoxide in the Emergency Room

Article

作者: Henriksen, Jakob Nørgaard ; Andersen, Charlotte Uggerhøj ; Illum, Dorte Goldbækdal ; Rosenquist, Sara Buttrup

ABSTRACTChlordiazepoxide is effective in treating alcohol withdrawal syndrome, but it poses a risk of long‐term sedation. The prevalence of this side effect and its risk factors remain uncertain. This retrospective cross‐sectional study aimed to estimate both using data from Aarhus University Hospital's BI portal. We identified and manually reviewed patient records from 1 September 2019 to 31 August 2021, including the treating physicians' conclusions on ICU admissions to determine whether they were likely due to chlordiazepoxide toxicity. Chlordiazepoxide was administered to 1363 unique patients in the study period. We identified 32 ICU admissions preceded by chlordiazepoxide administration, 5 of which (16%) were likely related to chlordiazepoxide toxicity. Patients with chlordiazepoxide‐induced admissions received higher cumulative doses compared to other admissions (425 mg vs. 150 mg, p = 0.01), had longer ICU stays (median 8 vs. 2 days, p = 0.01) and required higher doses of flumazenil (p = 0.04). Their median age was above 60 years, and not all had known liver disease. The overall incidence of long‐term chlordiazepoxide toxicity was approximately 0.35%, with risk factors including higher doses and age above 60. Our findings suggest increased caution when treating not only patients with liver disease but also elderly patients with chlordiazepoxide for alcohol withdrawal symptoms.